Zeer Exelixis / intent / exelixis

Exelixis

1001-5000 employees·Alameda, California, United States·exelixis.com

Observed, not inferred · updated weekly

Buying intent

24 tracked signals | Top 15 topics are below | Marketing and HR are carrying most of it.

17signals · 30 days
22topics tracked
37.5%attributed to a team

Attention by team

LinkedIn activity, by team

Where Exelixis's own people are actually spending their attention, by team, by topic. Bands run Low to High against the busiest pairing on this page, and each cell also shows how much of that team's own activity it represents.

High-impact system
Hiring
GTM Planning
Operational Excellence
Credit Risk
Liquidity Risk
Marketing
High50% of team Marketing to High-impact system: High, 50% of this team's signals
High50% of team Marketing to Hiring: High, 50% of this team's signals
Marketing to GTM Planning: no signal
Marketing to Operational Excellence: no signal
Marketing to Credit Risk: no signal
Marketing to Liquidity Risk: no signal
HR
High100% of team HR to High-impact system: High, 100% of this team's signals
HR to Hiring: no signal
HR to GTM Planning: no signal
HR to Operational Excellence: no signal
HR to Credit Risk: no signal
HR to Liquidity Risk: no signal
Others
Others to High-impact system: no signal
High20% of team Others to Hiring: High, 20% of this team's signals
High20% of team Others to GTM Planning: High, 20% of this team's signals
High20% of team Others to Operational Excellence: High, 20% of this team's signals
High20% of team Others to Credit Risk: High, 20% of this team's signals
High20% of team Others to Liquidity Risk: High, 20% of this team's signals
LowMediumHigh·  banded against the busiest pairing on this page

Topics being researched

30-day window

Every tracked topic, ranked by volume, not by our guess at what matters. Confidence is the classifier's own certainty that a signal belongs where we've filed it.

High-impact system
LinkedIn
High volume
98%
last
16d ago
Hiring
LinkedIn
High volume
95%
last
12d ago
GTM Planning
LinkedIn
Medium volume
98%
last
18d ago
Operational Excellence
LinkedIn
Medium volume
94%
last
12d ago
Credit Risk
LinkedIn
Medium volume
96%
last
24d ago
Liquidity Risk
LinkedIn
Medium volume
98%
last
24d ago
Cancer Research
LinkedIn
Medium volume
94%
last
12d ago
Artificial Intelligence
LinkedIn
Medium volume
96%
last
25d ago
Agentic AI System
LinkedIn
Medium volume
98%
last
25d ago
Social Learning
LinkedIn
Medium volume
96%
last
26d ago
Marketing Strategy
LinkedIn
Medium volume
98%
last
16d ago
Financial Services
LinkedIn
Medium volume
83%
last
31d ago
Executive Education
LinkedIn
Medium volume
98%
last
25d ago
Career Development
LinkedIn
Medium volume
98%
last
24d ago
Account-Based Marketing (ABM)
LinkedIn
Medium volume
94%
last
18d ago

Need intent for a specific topic or industry?

We track the full taxonomy across every account in the graph — including themes not shown on this page.

Talk to us

Who's active at Exelixis

verified title on file

Titles, seniority and topic straight from each person's own activity, with a LinkedIn link so you can check any of them yourself.

Others4 active
researching Clinical Trials
in
Directorresearching Go to Market
in
Leadershipresearching Risk Management
in
Directorresearching Startups
in
Marketing2 active
researching High-impact system
in
researching Hiring
in
HR1 active
Directorresearching Executive Education
in
Security1 active
Directorresearching Financial Services
in
Product1 active
Leadershipresearching Career Development
in

Primary products / business lines

LinkedIn company profile

Every Exelixis employee is united in an ambitious cause: to transform science into new treatments that give cancer patients and their families hope for the future. In this pursuit, we know our employees are our most valuable asset. As a diverse, growing team, everyone at Exelixis plays a role in advancing our mission through our innovative drug discovery, development and commercialization efforts.

Top accounts researching Exelixis

names withheld on the public page

These are companies whose own people brought up Exelixis unprompted, not accounts we guessed might be interested. We can't yet tell an implementation partner from a genuine buyer here, names unlock along with the buyer profile below.

6,390 companies · 20,106 people are researching High-impact system

Exelixis's own team shows 2 signals on this topic. No one outside Exelixis has been seen researching the company by name yet — so this is the market it sits in, not a list of its buyers.

  • Hiring75,708 cos · 411,263 people
  • GTM Planning2,773 cos · 6,458 people
Sign up to see which companies →

Buyer profile

company size · seniority

Company size and how senior the people involved are, the two things that decide whether this is a real deal. Competitor overlap isn't computed yet for this account.

Unlock the buyer profile

Company-size breakdown and buyer seniority mix for accounts researching Exelixis.

Company size breakdown
Buyer seniority mix

Sign up to learn more

Create an account to explore buyer insights as they become available.

Sign up to learn more →

Buying committee functions

Employee job titles (LinkedIn)

Marketing — 2 people; HR / Talent — 2 people; Product — 1 person; Security — 1 person

What's been said

public posts by Exelixis's team

No public post naming Exelixis has surfaced in the past year, so this is what Exelixis's own team is posting about publicly — their topics, in their words.

LinkedIn

We’ve added some great folks to our team in the last few months, like Jenna Rodeawald , and I’m excited that we have space for a couple more as we gear up for launch. Reach out to learn more about the opportunities in our Alameda office!

May 2026
LinkedIn

Thank you, Ryan Murr , Branden Berns and the other excellent legal professionals at Gibson Dunn who worked with the Cytokinetics team so effectively during an historic week for the company.

May 2026
LinkedIn

#ESMO25 was a success! My focus was on intensive investigator meetings strategizing on the next wave of clinical trials for our assets. • I engaged in many discussions with leading global investigators on trial designs that incorporates the new ESMO data, focusing on: • Biomarker-Driven Trials: Designing studies to better identify the patients who will benefit most from emerging therapies. • Novel Combinations: Planning the subsequent steps for agents, moving them into earlier disease settings or combining them with other innovative modalities. • Global Collaboration: Coordinating efforts across continents to ensure efficient, impactful clinical programs that accelerate drug development. The collaborative spirit was truly inspiring, solidifying our shared commitment to expediting therapeutic innovation for patients worldwide. Huge thanks to the investigators, researchers, whose dedication made this year's ESMO a remarkable success. Back to our campus to turn strategy into action!

Oct 2025
Straight from Exelixis: 7 earnings calls and filings read in full. Leadership's own words on the public record — not analyst commentary.

Strategic priorities

Earnings call; SEC filings

Market Share; Research and Development

What changed recently

Earnings call; SEC filings

Market Share; Research and Development

About this data. Exelixis (exelixis.com). Department attribution is 37.5%; remaining activity is grouped under Others. Updated 2026-10-03T14:00:03.490Z.

Not yet computedPer-team narrative summaries